undamentalytics Newsletter
Sign in

4d Molecular Therapeutics, Inc. cash flow statement

In fiscal 2025, 4d Molecular Therapeutics, Inc.'s operations generated −$109m of cash; it spent $536,000 on capital projects, leaving free cash flow of −$110m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−37−51−69−87−76−135−109−156
Depreciation and amortisation11224555
Stock-based pay45141720262220
Capital spending319123410
Free cash flow−40−52−78−98−79−138−110−156
Free cash flow after stock pay−43−57−92−115−98−164−132−176
Shares issued—2061140————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: FDMT vs VSTMAGIO vs FDMTFDMT vs SEPN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from 4d Molecular Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to 4d Molecular Therapeutics, Inc.